How many companies are developing new antibiotics in order to tackle antibiotic-resistant infections? Not enough.
Many medical breakthroughs in the last century could ultimately be labelled as worthless or lost through the spread of antimicrobial resistance.
New resistance mechanisms have emerged and are spreading globally, threatening the pharmaceuticals industries ability to treat infectious illnesses and diseases.
Australian biotech company, Opal Biosciences, is committed to tackling this serious global threat.